Biotechnology executive order opens door for regulatory reform and social acceptance of genetically engineered microbes in agriculture.


Journal

GM crops & food
ISSN: 2164-5701
Titre abrégé: GM Crops Food
Pays: United States
ID NLM: 101572655

Informations de publication

Date de publication:
31 Dec 2024
Historique:
medline: 28 7 2024
pubmed: 28 7 2024
entrez: 27 7 2024
Statut: ppublish

Résumé

In the United States, regulatory review of genetically engineered microbes for agriculture falls under the Coordinated Framework for the Regulation of Biotechnology (CFRB). However, the lack of a centralized regulatory pathway and multiple oversight authorities can lead to uncertainty in regulatory review. Using three microbial-based technologies for agriculture as illustrative examples, this commentary identifies the weaknesses and challenges associated with the CFRB by assessing the current system and proposed changes to the system under a multi criteria decision analysis framework. In addition, it discusses opportunities for regulatory reform to improve clarity, efficiency, and public acceptance of genetically engineered microbes in agriculture under the CHIPS and Science Act and the 2022 Executive Order on the Bioeconomy.

Identifiants

pubmed: 39066641
doi: 10.1080/21645698.2024.2381294
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

248-261

Auteurs

Jabeen Ahmad (J)

Department of Plant and Microbial Biology, North Carolina State University, Raleigh, NC, USA.
Genetic Engineering and Society Center, North Carolina State University, Raleigh, NC, USA.

Amy Grunden (A)

Department of Plant and Microbial Biology, North Carolina State University, Raleigh, NC, USA.
Genetic Engineering and Society Center, North Carolina State University, Raleigh, NC, USA.

Jennifer Kuzma (J)

Genetic Engineering and Society Center, North Carolina State University, Raleigh, NC, USA.
School of Public and International Affairs, North Carolina State University, Raleigh, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH